Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Secondary Hyperparathyroidism: later-stage trial registry
2 of 9 indexed Secondary Hyperparathyroidism trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 2 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Secondary Hyperparathyroidism: 9 US clinical trials tracked, 2 recruiting.
Secondary Hyperparathyroidism is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Genzyme, a Sanofi Company, running 3 of these trials.
Enrollment posture brief
Registry condition secondary-hyperparathyroidism
OPEN 2 | RECR 22% | LATE 6 | EARLY 2 | RANK #1916 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acne (22% recruiting · 27 trials)
Secondary Hyperparathyroidism lists 2 open slots (22% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Secondary Hyperparathyroidism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Secondary Hyperparathyroidism is recruiting below its size-band peers.
2 of 9 indexed trials (22.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Secondary Hyperparathyroidism research.
Genzyme, a Sanofi Company accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Secondary Hyperparathyroidism trials plan to enrol fewer than 100 people.
Median target enrolment is 56 among the 9 trials that report a genuine target (sentinel values excluded). 8 of those (88.9%) plan for fewer than 100 participants.
-
Secondary Hyperparathyroidism research is mostly interventional.
8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Amgen
NCT03633708
Precision Medicine Approaches to Renal Osteodystrophy
Thomas Nickolas
NCT05880914
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Amgen
NCT00261950
Trial to Optimize Mineral Outcomes in Dialysis Patients
University of Colorado, Denver
NCT01100723
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
Genzyme, a Sanofi Company
NCT00123461
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
Weill Medical College of Cornell University
NCT00288873
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
Deltanoid Pharmaceuticals
NCT01653379
A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis
Genzyme, a Sanofi Company
NCT00418600
A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis
Genzyme, a Sanofi Company
NCT00454350
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Secondary Hyperparathyroidism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Secondary Hyperparathyroidism trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Secondary Hyperparathyroidism page
9 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Secondary Hyperparathyroidism trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Genzyme, a Sanofi Company sponsors the most Secondary Hyperparathyroidism trials on record, review their full trial history before evaluating a specific study. See Genzyme, a Sanofi Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Secondary Hyperparathyroidism condition card totals 9 registered trials; most-linked intervention Sensipar (Cinacalcet HCl); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.